Evidence map›Paper›PMID 31147552›Full record

ArticleNature communications2019

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

Jennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, Ruping Sun, Zheng Hu, Zhicheng Ma, Jie Ding, Carlos J Suarez, Susanne Tilk, Akshara Raghavendra and 10 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 2 countries.

Jennifer L Caswell-JinDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, 94305, California, United States.ORCID http://orcid.org/0000-0002-5711-8355
Katherine McNamaraDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, 94305, California, United States.ORCID http://orcid.org/0000-0002-3717-6494
Johannes G ReiterCanary Center for Cancer Early Detection, Department of Radiology, Stanford University School of Medicine, Palo Alto, 94305, CA, USA.ORCID http://orcid.org/0000-0002-0170-7353
Ruping SunDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, 94305, California, United States.ORCID http://orcid.org/0000-0003-3702-9483
Zheng HuDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, 94305, California, United States.
Zhicheng MaDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, 94305, California, United States.
Jie DingDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, 94305, California, United States.
Carlos J SuarezDepartment of Pathology, Stanford University School of Medicine, Stanford, 94305, CA, USA.
Susanne TilkDepartment of Biology, Stanford University, Stanford, 94305, CA, USA.
Akshara RaghavendraDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, TX, USA.
Victoria ForteMaimonides Medical Center, Brooklyn, 11219, NY, USA.
Suet-Feung ChinCancer Research UK Cambridge Institute, Department of Oncology, University of Cambridge, Cambridge, CB2 0RE, UK.ORCID http://orcid.org/0000-0001-5697-1082
Helen BardwellCancer Research UK Cambridge Institute, Department of Oncology, University of Cambridge, Cambridge, CB2 0RE, UK.
Elena ProvenzanoCambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Carlos CaldasCancer Research UK Cambridge Institute, Department of Oncology, University of Cambridge, Cambridge, CB2 0RE, UK.ORCID http://orcid.org/0000-0003-3547-1489
Julie LangNorris Comprehensive Cancer Center, Los Angeles, 90033, CA, USA.ORCID http://orcid.org/0000-0002-7534-6124
Robert WestDepartment of Pathology, Stanford University School of Medicine, Stanford, 94305, CA, USA.
Debu TripathyDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, TX, USA.ORCID http://orcid.org/0000-0002-5711-2404
Michael F PressNorris Comprehensive Cancer Center, Los Angeles, 90033, CA, USA.
Christina CurtisDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, 94305, California, United States. cncurtis@stanford.edu.ORCID http://orcid.org/0000-0003-0166-3802
Stanford University · USUniversity of Cambridge · GBThe University of Texas MD Anderson Cancer Center · USUniversity of Southern California · USCambridge University Hospitals NHS Foundation Trust · GBMaimonides Medical Center · USPalo Alto University · USStanford Medicine · US

Funding

INSTITUTIONAL TRAINING GRANT IN GENOME SCIENCET32HG000044 · NHGRI · STANFORD UNIVERSITY · PI MICHAEL P. SNYDER · 1995 to 2026
$32.2M
Cancer Research UK 16942NHGRI NIH HHS T32 HG000044
6 · The paper itself

Abstract

The original version of this Article omitted from the Author Contributions statement that 'R.S. and J.G.R contributed equally to this work.' This has been corrected in both the PDF and HTML versions of the Article.

Identifiers

PMID31147552
PMCPMC6542801
OpenAlexW2947346403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.